C.Q. Pharmaceutical Holding (000950.SZ), a shareholder of Drug Friend Pharmaceutical, signed a licensing agreement with Pfizer.

C.Q. Pharmaceutical Holding (000950.SZ) announced that its subsidiary, Chongqing Pharmaceuticals (Group) Co., Ltd., holds a 38.67% stake in Chongqing Yaoyou Pharmaceutical Co., Ltd. (referred to as "Yaoyou Pharmaceutical"). Yaoyou Pharmaceutical has granted Pfizer exclusive rights in the licensed territory (global scope) and field (treatment, diagnosis, and prevention of all indications in humans and animals) for the development, use, production, and commercialization of oral small molecule Glucagon-like Peptide-1 Receptor (GLP-1R) agonists (including YP05002) and products containing this active ingredient. Under this license agreement, Yaoyou Pharmaceutical will have the right to receive a non-refundable upfront payment of $150 million and development milestone payments of up to $350 million based on clinical and commercial progress of the licensed products. The announcement states that YP05002 is an orally administered small molecule GLP-1R agonist developed and owned by Yaoyou Pharmaceutical with proprietary intellectual property rights. It primarily works by activating human GLP-1R, promoting insulin secretion from the pancreas, reducing glucagon secretion, inhibiting gastric emptying and intestinal motility, and reducing energy intake by affecting the central nervous system to suppress appetite. It is used for the treatment of type 2 diabetes, obesity, and related diseases. YP05002 is intended for the treatment of metabolic disorders, with potential indications including long-term weight management, type 2 diabetes, and metabolic dysfunction-related non-alcoholic fatty liver disease.